Association of the TLR4 signaling pathway in the retina of streptozotocin-induced diabetic rats

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 253, Issue 3, 2015, Pages 389-398

  Wang, Yan Ling ^a   Wang, Kang ^a   Yu, Shu Jing ^a   Li, Qian ^a   Li, Na ^a   Lin, Peng Yao ^a   Li, Ming Ming ^a   Guo, Jian You ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF PSYCHOLOGY   (China)

Author keywords

Diabetes; Diabetic retinopathy; Streptozotocin; TAK 242; Toll like receptor 4

Indexed keywords

ACRIDINE ORANGE; BETA INTERFERON; EVANS BLUE; INTERLEUKIN 1BETA; RESATORVID; STREPTOZOCIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; BLOOD GLUCOSE; ETHYL 6-(N-(2-CHLORO-4-FLUOROPHENYL)SULFAMOYL)CYCLOHEX-1-ENE-1-CARBOXYLATE; INTERFERON-BETA; INTERLEUKIN-1BETA; SULFONAMIDES; TLR4 PROTEIN, RAT; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FLUOROGRAPHY; IN VIVO STUDY; LEUKOCYTE; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; WESTERN BLOTTING; ANIMALS; ANTAGONISTS AND INHIBITORS; BLOOD GLUCOSE; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETICS; INJECTIONS, INTRAPERITONEAL; LEUKOCYTE COUNT; MALE; METABOLISM; PHYSIOLOGY; RATS; RATS, INBRED BN; REAL-TIME POLYMERASE CHAIN REACTION; RETINA;

ANIMALS; BLOOD GLUCOSE; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; INJECTIONS, INTRAPERITONEAL; INTERFERON-BETA; INTERLEUKIN-1BETA; LEUKOCYTE COUNT; MALE; RATS; RATS, INBRED BN; REAL-TIME POLYMERASE CHAIN REACTION; RETINA; SIGNAL TRANSDUCTION; SULFONAMIDES; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928790710     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-014-2832-y     Document Type: Article

References (39)

1. Karadayi K, Top C, Gulecek O (2003) The relationship between soluble L-selectin and the development of diabetic retinopathy. Ocul Immunol Inflamm 11:123–129
2. Lu B, Wen J, Song XY, Dong XH, Yang YH, Zhang ZY, Zhao NQ, Ye HY, Mou B, Chen FL, Liu Y, Shen Y, Wang XC, Zhou LN, Li YM, Zhu XX, Hu RM (2007) High prevalence of albuminuria in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract 75:184–192
3. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI (2006) Neuroprotective and blood–retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168:235–244
4. Amadio M, Bucolo C, Leggio GM, Drago F, Govoni S, Pascale A (2010) The PKCbeta/HuR/VEGF pathway in diabetic retinopathy. Biochem Pharmacol 80:1230–1237
5. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I (2006) Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55:774–779
6. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, Tsubota K, Itoh H, Oike Y, Ishida S (2009) Prorenin receptor-mediated signal transduction and tissue renin–angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 58:1625–1633
7. Tang J, Kern TS (2011) Inflammation in diabetic retinopathy. Prog Retin Eye Res 30:343–358
8. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450–1452
9. Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y (1998) In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 39:2190–2194
10. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP (1999) Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 96:10836–10841
11. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D’Amore PA, Shima DT, Adamis AP (2003) VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198:483–489
12. Wong FS, Hu C, Zhang L, Du W, Alexopoulou L, Flavell RA, Wen L (2008) The role of Toll-like receptors 3 and 9 in the development of autoimmune diabetes in NOD mice. Ann N Y Acad Sci 1150:146–148
13. Akira S, Takeda K, Kaisho T (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2:675–680
14. Lee MS, Kim YJ (2007) Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 76:447–480
15. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR (2006) Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26:430–437
16. Yi H, Patel AK, Sodhi CP, Hackam DJ, Hackam AS (2012) Novel role for the innate immune receptor Toll-like receptor 4 (TLR4) in the regulation of the Wnt signaling pathway and photoreceptor apoptosis. PLoS One 7:e36560
17. Dvoriantchikova G, Barakat DJ, Hernandez E, Shestopalov VI, Ivanov D (2010) Toll-like receptor 4 contributes to retinal ischemia/reperfusion injury. Mol Vis 16:1907–1912
18. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I (2008) Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 93:578–583
19. Devaraj S, Dasu MR, Park SH, Jialal I (2009) Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 52:1665–1668
20. Devaraj S, Tobias P, Jialal I (2011) Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine 55:441–445
21. Jiang G, Ke Y, Sun D, Wang Y, Kaplan HJ, Shao H (2009) Regulatory role of TLR ligands on the activation of autoreactive T cells by retinal astrocytes. Invest Ophthalmol Vis Sci 50:4769–4776
22. Luo C, Yang X, Kain AD, Powell DW, Kuehn MH, Tezel G (2010) Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling. Invest Ophthalmol Vis Sci 51:5697–5707
23. Gnana-Prakasam JP, Martin PM, Mysona BA, Roon P, Smith SB, Ganapathy V (2008) Hepcidin expression in mouse retina and its regulation via lipopolysaccharide/Toll-like receptor-4 pathway independent of Hfe. Biochem J 411:79–88
24. Wang K, Wang Y, Gao L, Li X, Li M, Guo J (2008) Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 31:1541–1546
25. Wang YC, Wang PF, Fang H, Chen J, Xiong XY, Yang QW (2013) Toll-like receptor 4 antagonist attenuates intracerebral hemorrhage-induced brain injury. Stroke 44:2545–2552
26. Seki H, Tasaka S, Fukunaga K, Shiraishi Y, Moriyama K, Miyamoto K, Nakano Y, Matsunaga N, Takashima K, Matsumoto T, Ii M, Ishizaka A, Takeda J (2010) Effect of Toll-like receptor 4 inhibitor on LPS-induced lung injury. Inflamm Res 59:837–845
27. Bucolo C, Ward KW, Mazzon E, Cuzzocrea S, Drago F (2009) Protective effects of a coumarin derivative in diabetic rats. Invest Ophthalmol Vis Sci 50:3846–3852
28. Bucolo C, Leggio GM, Drago F, Salomone S (2012) Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Biochem Pharmacol 84:88–92
29. Guo JY, Li CY, Ruan YP, Sun M, Qi XL, Zhao BS, Luo F (2009) Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 612:54–60
30. Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221–229
31. Yan JE, Yuan W, Lou X, Zhu T (2012) Streptozotocin-induced diabetic hyperalgesia in rats is associated with upregulation of Toll-like receptor 4 expression. Neurosci Lett 526:54–58
32. Miyamoto K, Ogura Y, Kenmochi S, Honda Y (1997) Role of leukocytes in diabetic microcirculatory disturbances. Microvasc Res 54:43–48
33. Miyahara S, Kiryu J, Yamashiro K, Miyamoto K, Hirose F, Tamura H, Katsuta H, Nishijima K, Tsujikawa A, Honda Y (2004) Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol 164:1697–1706
34. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV (2009) Toll-like receptors in neurodegeneration. Brain Res Rev 59:278–292
35. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I (2008) High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 57:3090–3098
36. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Muhlradt PF, Akira S (2000) Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol 164:554–557
37. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301:640–643
38. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM, Eritoran Sepsis Study G (2010) Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 38:72–83
39. Ii M, Matsunaga N, Hazeki K, Nakamura K, Takashima K, Seya T, Hazeki O, Kitazaki T, Iizawa Y (2006) A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 69:1288–1295